Targeting cancer with PI3K pathway inhibitors: who to aim at?

被引：2
|
作者：
Kinross, Kathryn M. [1 ,4 ]
Sheppard, Karen E. [1 ,3 ]
Pearson, Richard B. [1 ,3 ,4 ]
Phillips, Wayne A. [1 ,2 ,3 ,4 ,5 ]
机构：
[1] Peter MacCallum Canc Ctr, Canc Res Div, East Melbourne, Vic, Australia
[2] Peter MacCallum Canc Ctr, Canc Surg Div, East Melbourne, Vic, Australia
[3] Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia
[4] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic 3052, Australia
[5] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic, Australia
来源：
TRANSLATIONAL CANCER RESEARCH | 2012年 / 1卷 / 02期
关键词：
D O I：
10.3978/j.issn.2218-676X.2012.03.06
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：119 / 121
页数：3
相关论文
共 50 条
  • [21] Drug discovery approaches targeting the PI3K/Akt pathway in cancer
    Garcia-Echeverria, C.
    Sellers, W. R.
    ONCOGENE, 2008, 27 (41) : 5511 - 5526
  • [22] Drug discovery approaches targeting the PI3K/Akt pathway in cancer
    C Garcia-Echeverria
    W R Sellers
    Oncogene, 2008, 27 : 5511 - 5526
  • [23] Targeting the PI3K signaling pathway in KRAS mutant colon cancer
    Hong, Suntaek
    Kim, SoYoung
    Kim, Hye Youn
    Kang, Myunghee
    Jang, Ho Hee
    Lee, Won-Suk
    CANCER MEDICINE, 2016, 5 (02): : 248 - 255
  • [24] Targeting the PI3K/Akt/mTOR pathway for cancer prevention.
    Dennis, PA
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (11) : 2800S - 2801S
  • [25] Targeting the PI3K/Akt/mTOR Pathway for Breast Cancer Therapy
    Justin Cidado
    Ben Ho Park
    Journal of Mammary Gland Biology and Neoplasia, 2012, 17 : 205 - 216
  • [26] Will PI3K pathway inhibitors be effective as single agents in patients with cancer?
    Garrett, Joan T.
    Chakrabarty, Anindita
    Arteaga, Carlos L.
    ONCOTARGET, 2011, 2 (12) : 1314 - 1321
  • [27] Targeting the PI3K/AKT/mTOR pathway in lung cancer: mechanisms and therapeutic targeting
    Qiang, Min
    Chen, Zhe
    Liu, Hongyang
    Dong, Junxue
    Gong, Kejian
    Zhang, Xinjun
    Huo, Peng
    Zhu, Jingjun
    Shao, Yifeng
    Ma, Jinazun
    Zhang, Bowei
    Liu, Wei
    Tang, Mingbo
    FRONTIERS IN PHARMACOLOGY, 2025, 16
  • [28] Predictive and pharmacodynamic (PD) markers of PI3K pathway inhibitors: focus on PI3K, AKT and mTOR inhibitors
    Tabernero, J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S6 - S6
  • [29] Multipoint targeting of the PI3K/mTOR pathway in mesothelioma
    Zhou, S.
    Liu, L.
    Li, H.
    Eilers, G.
    Kuang, Y.
    Shi, S.
    Yan, Z.
    Li, X.
    Corson, J. M.
    Meng, F.
    Zhou, H.
    Sheng, Q.
    Fletcher, J. A.
    Ou, W-B
    BRITISH JOURNAL OF CANCER, 2014, 110 (10) : 2479 - 2488
  • [30] Targeting the PI3K/mTOR pathway hematologic malignancies
    Tasian, Sarah K.
    Teachey, David T.
    Rheingold, Susan R.
    FRONTIERS IN ONCOLOGY, 2014, 4
12345